Pfizer Inc. is one of the world's largest pharmaceutical companies, with a legacy spanning over 175 years since its founding in 1849 by Charles Pfizer and Charles Erhart in Brooklyn, New York. Headquartered in New York City, Pfizer employs over 80,000 people worldwide and maintains a market capitalization of approximately $160 billion USD[1].
While Pfizer discontinued its internal neuroscience discovery programs in 2018, the company has strategically maintained its commitment to neurodegenerative disease research through partnerships, equity investments, and acquisitions. The most notable example is the 2022 acquisition of Biohaven Pharmaceuticals for $11.6 billion, which gave Pfizer the leading CGRP (calcitonin gene-related peptide) migraine franchise[2].
Pfizer's approach to neurodegeneration reflects a broader industry trend toward external innovation, leveraging partnerships with biotechnology companies to access novel therapeutic modalities without maintaining expensive internal discovery infrastructure.
Pfizer was founded in 1849 by cousins Charles Pfizer and Charles Erhart, initially producing chemical compounds. The company gained prominence during World War I when it pioneered citric acid production using fermentation technology, a capability that later proved invaluable for antibiotic production[3].
The latter half of the 20th century saw Pfizer transform into a major pharmaceutical force:
Following the 2018 strategic decision to discontinue internal neuroscience discovery, Pfizer's approach to neurodegenerative diseases has focused on three pillars[4]:
| Program | Target/Mechanism | Indication | Phase | Partner |
|---|---|---|---|---|
| ACI-35.030 | Tau phosphorylation vaccine | AD | Phase 1/2 | AC Immune |
| ACI-35.016 | Tau vaccine | AD | Phase 1 | AC Immune |
| RG6102 | Anti-tau mAb | AD | Phase 2 | Roche |
ACI-35 (with AC Immune) is a liposome-based tau vaccine designed to induce antibodies against phosphorylated tau proteins. The Phase 1/2 study is evaluating safety, immunogenicity, and biomarker effects in patients with early Alzheimer's disease[5].
| Program | Target/Mechanism | Indication | Phase | Partner |
|---|---|---|---|---|
| DNL151 (BIIB122) | LRRK2 inhibitor | PD | Phase 1b | Denali |
| BIIB060 | LRRK2 inhibitor | PD | Phase 1 | Denali |
DNL151 (BIIB122) is a LRRK2 kinase inhibitor co-developed with Denali Therapeutics. LRRK2 (leucine-rich repeat kinase 2) mutations are among the most common genetic causes of familial Parkinson's disease, and LRRK2 hyperactivity may contribute to sporadic PD pathogenesis[6].
The Phase 1b study demonstrated:
Following the 2022 acquisition, Pfizer gained the leading CGRP migraine franchise[7]:
| Program | Target/Mechanism | Indication | Status |
|---|---|---|---|
| Rimegepant (Nurtec ODT) | CGRP receptor antagonist | Acute/Preventive migraine | Approved |
| Zavegepant | CGRP receptor antagonist | Acute migraine (nasal spray) | Approved |
| Rimegepant ODT | CGRP receptor antagonist | Preventive migraine | Approved |
Rimegepant (Nurtec ODT) is the only CGRP antagonist approved for both acute and preventive migraine treatment. The drug's dual indication and oral bioavailability have made it a commercial success, with over $600 million in annual revenue[8].
| Program | Target/Mechanism | Indication | Phase | Status |
|---|---|---|---|---|
| PF-06412562 | PDE10A inhibitor | Schizophrenia | Phase 1 | Discontinued |
| PF-5198237 | 5-HT1F agonist | Acute migraine | Phase 1 | Discontinued |
Pfizer's partnership with AC Immune focuses on tau-targeted therapies for Alzheimer's disease[5:1]:
The partnership with Denali focuses on LRRK2 inhibitors for Parkinson's disease[6:1]:
The 2022 acquisition of Biohaven Pharmaceuticals gave Pfizer[2:1][7:1]:
Pfizer's venture capital arm has invested in multiple neurodegeneration-focused companies:
The clinical development of rimegepant demonstrated[8:1]:
Acute Treatment (Phase 3):
Preventive Treatment (Phase 2/3):
The DNL151 Phase 1b study demonstrated[6:2]:
| Year | Revenue (USD) | Key Products | R&D Spend |
|---|---|---|---|
| 2023 | $58.5B | Comirnaty, Paxlovid, Nurtec | $10.5B |
| 2022 | $100.3B | Comirnaty, Paxlovid | $11.4B |
| 2021 | $81.3B | Comirnaty | $10.7B |
| 2020 | $41.9B | Prevnar, Eliquis | $9.4B |
Post-COVID, Pfizer is refocusing on traditional pharmaceutical revenue streams, with the Biohaven acquisition providing growth in migraine and expanding CNS presence[1:1].
Alzheimer's Disease:
Parkinson's Disease:
Migraine:
| Year | Program | Milestone |
|---|---|---|
| 2025 | ACI-35 | Phase 2 data expected |
| 2025 | BIIB122 | Phase 2b readout |
| 2026 | Zavegepant launch | Market expansion |